Antivirals may benefit some inpatients
Elevated virus levels in hospitalized COVID-19 patients’ blood predicts worsening respiratory symptoms and suggests ongoing viral replication in later disease stages, Stanford Medicine-led study says.
Possible treatment for mucus-induced lung diseases
Stanford Medicine investigators and their collaborators have designed a compound that’s uniquely capable of blocking excessive mucus secretion — a hallmark of several serious respiratory disorders.
Ami Bhatt on gut microbiomes
The Stanford Medicine professor on why it’s important to better understand the microbiome of people transitioning from traditional to Westernized lifestyles.
COVID-19 hospitalizations among kids likely overcounted
Children being treated in hospitals are tested for SARS-CoV-2, but many who test positive never develop COVID-19 symptoms, leading to overestimates of disease severity, a study found.
Study of COVID-19 saliva test
An at-home COVID-19 test, designed by Stanford researchers to be easy to use and provide results within 30 minutes, will be the focus of a study funded by the Stanford Medicine Catalyst Program.
Biomarker for lipedema discovered
Researchers have identified a molecule that ties lipedema to other lymphatic diseases, such as lymphedema, and distinguishes it from obesity.
New center for rare eye disease
A $10 million gift has enabled the launch of a center focusing on optic disc drusen, a poorly understood eye disease that can lead to visual impairment or even blindness.
Microbial loss, ulcerative colitis linked
Bacteria normally inhabiting healthy people’s intestines — and the anti-inflammatory metabolites these bacteria produce — are depleted in ulcerative colitis patients, a Stanford study shows.
Stanford-led teams nab top clinical research prizes
Winning studies were chosen by members of the Clinical Research Forum, a nonprofit foundation that promotes the understanding of clinical research and its impact on health and health care.
Inflammation turns mutation deadly
A simple viral infection in the lungs of rats can become a lethal form of pulmonary hypertension if a common mutation is present, new Stanford research shows.
Possible ‘bubble boy’ disease therapy
In preclinical trials, Stanford scientists and their collaborators harnessed the gene-editing system CRISPR-Cas9 to replace the mutated gene underpinning the devastating immune disease.
- Big Data
- Cardiovascular Health
- Chemical Biology
- Chronic Disease
- Developmental Biology
- Global Health
- Health Policy
- Infectious Disease
- Mental Health
- Patient Care
- Precision Health
- Preventive Medicine
- Stem Cells
- Women's Health